drugset
Drugs / AAA617
last change Sep 2025 re-read 3 minutes ago

AAA617

also known as [177Lu]Lu-PSMA-617 (AAA617) · lutetium (177Lu) vipivotide tetraxetan
Developed for
prostate carcinoma · castration-resistant prostate carcinoma · prostate cancer · prostate neoplasm
Investigated by
Novartis Pharmaceuticals

Trials 7

today NCT06894511 · Ph 2 NCT07047118 · Ph 2 NCT06531499 · Ph 1 NCT06004661 · Ph 2 NCT05939414 · Ph 3 NCT05849298 · Ph 2 NCT05803941 · Ph 4
2024202520262027202820292030203120322033
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06531499 Nov 2024 → Nov 2028 expected prostate carcinoma Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 24 trials
Phase 2 NCT06894511 Sep 2025 → Oct 2026 expected prostate carcinoma Novartis Pharmaceuticals Active not recruiting No outcome recorded
Phase 2 NCT07047118 Jul 2025 → Jul 2027 expected castration-resistant prostate carcinoma Novartis Pharmaceuticals Active not recruiting No outcome recorded
Phase 2 NCT06004661 Apr 2024 → Dec 2026 expected castration-resistant prostate carcinoma Novartis Pharmaceuticals Active not recruiting No outcome recorded
Phase 2 NCT05849298 Jan 2024 → Dec 2026 expected prostate neoplasm Novartis Pharmaceuticals Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT05939414 Mar 2024 → Apr 2028 expected prostate carcinoma Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT05803941 Aug 2023 → Jul 2033 expected prostate cancer Novartis Pharmaceuticals Recruiting No outcome recorded
Comparator or background therapy1 trial
Phase 3 NCT06855277 Comparator Jul 2025 → Sep 2028 expected prostate cancer Novartis Pharmaceuticals Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as AAA617 “The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel or \[177Lu\]Lu-PSMA-617 (AAA617).” NCT06855277 ↗
7

NCT06531499 ↗

NCT06004661 ↗

NCT05939414 ↗

NCT07047118 ↗

NCT06894511 ↗

NCT05849298 ↗

NCT05803941 ↗
Known as [177Lu]Lu-PSMA-617 (AAA617) “[177Lu]Lu-PSMA-617 (AAA617)” NCT06855277 ↗
Known as lutetium (177Lu) vipivotide tetraxetan “This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of...” NCT06004661 ↗
Route Intravenous “Administration intravenously once every 6 weeks (1 cycle) for 6 cycles” NCT05849298 ↗